An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalie E Stevens, Cara K Fraser, Mohammed Alsharifi, Michael P Brown, Kerrilyn R Diener, John D Hayball
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f57c6ebaae0d4f3ea32cdc726b166c2a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f57c6ebaae0d4f3ea32cdc726b166c2a
record_format	dspace
spelling	oai:doaj.org-article:f57c6ebaae0d4f3ea32cdc726b166c2a2021-11-18T09:03:33ZAn empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.1932-620310.1371/journal.pone.0068895https://doaj.org/article/f57c6ebaae0d4f3ea32cdc726b166c2a2013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23894371/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT™ was compared to Freund's adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT™ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund's adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together, these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies specifically for the prevention and treatment of globally significant diseases.Natalie E StevensCara K FraserMohammed AlsharifiMichael P BrownKerrilyn R DienerJohn D HayballPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 7, p e68895 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Natalie E Stevens Cara K Fraser Mohammed Alsharifi Michael P Brown Kerrilyn R Diener John D Hayball An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
description	Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT™ was compared to Freund's adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT™ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund's adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together, these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies specifically for the prevention and treatment of globally significant diseases.
format	article
author	Natalie E Stevens Cara K Fraser Mohammed Alsharifi Michael P Brown Kerrilyn R Diener John D Hayball
author_facet	Natalie E Stevens Cara K Fraser Mohammed Alsharifi Michael P Brown Kerrilyn R Diener John D Hayball
author_sort	Natalie E Stevens
title	An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
title_short	An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
title_full	An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
title_fullStr	An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
title_full_unstemmed	An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
title_sort	empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant covaccine ht™ is functionally superior to freund's adjuvant.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/f57c6ebaae0d4f3ea32cdc726b166c2a
work_keys_str_mv	AT natalieestevens anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT carakfraser anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT mohammedalsharifi anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT michaelpbrown anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT kerrilynrdiener anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT johndhayball anempiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT natalieestevens empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT carakfraser empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT mohammedalsharifi empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT michaelpbrown empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT kerrilynrdiener empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant AT johndhayball empiricalapproachtowardstheefficientandoptimalproductionofinfluenzaneutralizingovinepolyclonalantibodiesdemonstratesthatthenoveladjuvantcovaccinehtisfunctionallysuperiortofreundsadjuvant
_version_	1718421000665694208

An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Ejemplares similares